Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke
Top Cited Papers
- 4 February 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 107 (4) , 598-603
- https://doi.org/10.1161/01.cir.0000046451.38849.90
Abstract
Background— Matrix metalloproteinase (MMP) expression is related to blood brain barrier disruption after cerebral ischemia. Moreover, MMP inhibitors reduce hemorrhagic transformation (HT) after emb...Keywords
This publication has 17 references indexed in Scilit:
- Thrombolysis-Related Hemorrhagic InfarctionStroke, 2002
- Markers of Increased Risk of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke in Clinical PracticeCirculation, 2002
- Carbohydrate source influences gelatinase production by mouse astrocytes in vitroGlia, 2002
- Matrix Metalloproteinases Increase Very Early during Experimental Focal Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 1999
- Matrix Metalloproteinases in Cerebrovascular DiseaseJournal of Cerebral Blood Flow & Metabolism, 1998
- Hemorrhagic Transformation and Microvascular Integrity during Focal Cerebral Ischemia/ReperfusionJournal of Cerebral Blood Flow & Metabolism, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Thrombolytic Agents in the Treatment of StrokeClinical Neuropharmacology, 1990
- Metalloproteinases and their inhibitors in matrix remodelingTrends in Genetics, 1990